Shares of Elicio Therapeutics Inc. (ELTX) touched a new high of $12.42 in early trading today, as investors await a major clinical trial milestone in the coming months, particularly in the fourth quarter.
Elicio is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. Its lead investigational asset is ELI-002, a lymph node-targeted mutant Kristen rat sarcoma (mKRAS) cancer vaccine.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com